TABLE 3

Studies investigating dupilumab in treating allergic bronchopulmonary aspergillosis (ABPA)

Author [ref.]Type of studyPatients nSex (M:F)Age (years)Cystic fibrosis (yes/no)ABPA (yes/no)Reason for dupilumab administrationObjectivesDupilumab dosageTreatment durationFollow-upResultsBenefit (yes/no)
Eraso [50]ReviewNANANANANANANANANANANANA
Ramonell [46]Case series31:233–60NoYesPoor response to CSS
CSS dependence
Incomplete response to omalizumab and/or mepolizumab
NSNS6 monthsNSSymptoms resolution
No exacerbations
CSS use reduction/suspension
↑ FEV1
↓ total IgE
↑ AEC (2/3)
A patient hospitalised for asthma exacerbation probably due to dupilumab-induced hypereosinophilia
Yes
Mümmler [45]Case report10:149NoYesCSS side-effects
CSS dependence
Incomplete or no response to benralizumab and omalizumab
NS600 mg loading dose, then 300 mg s.c. every 2 weeks8 monthsNSSymptom improvement
Oral CSS suspension
↑ FEV1
FENO
↓ total IgE
↑ AEC (transient)
Yes
Ali [47]Case report10:160NoYesCSS side-effects
CSS dependence
Omalizumab hypersensitivity reaction
NS300 mg s.c. every 2 weeks4 monthsNSSymptoms improvement
↓ oral CSS
↓ total IgE
Yes
Mikura [48]Case report11:045NoYesCSS dependence
No improvement with mepolizumab
NS600 mg loading dose, then 300 mg s.c. every 2 weeks12 monthsNAOral CSS suspension
Radiological resolution
↓ total IgE
Yes
Nishimura [49]Case report1NANANANANANANANANANANA

M: male; F: female; NA: not applicable; CSS: corticosteroids; s.c.: subcutaneous; NS: not specified; AEC: absolute eosinophil count; FENO: fractional exhaled nitric oxide.